Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

Table 1

Baseline demographic characteristics.

Number of evaluable patients	97
Median age at diagnosis (range)	51 (32–76)
TNM stage [𝑛 (%)]
I	20 (20.6%)
II	41 (42.3%)
IIA	4 (4.1%)
IIB	5 (5.2%)
III	21 (21.6%)
IIIA	5 (5.2%)
Unknown	1 (1.0%)
Type of surgery [𝑛 (%)]
Mastectomy	51 (52.6%)
Wide local excision	46 (47.4%)
Chemotherapy regimen [𝑛 (%)]
Primary	20 (20.4%)
Adjuvant	78 (79.6%)
Anthracycline regimen [𝑛 (%)]*
AC	4 (4.1%)
AC + T	77 (79.4%)
TAC	16 (16.5%)
Trastuzumab [𝑛 (%)]
Yes	15 (15.5 %)
No	70 (72.2%)
Unknown	12 (12.4%)
Radiotherapy [𝑛 (%)]
Yes	78 (80.4%)
No	19 (19.6%)
Endocrine therapy
Yes	72 (74.2%)
No	5 (5.2%)
Unknown	20 (20.6%)

∗AC: 6 cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²).
AC + T: 4 cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²) followed by 4 cycles of docetaxel (75 mg/m²).
TAC: six cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²) and docetaxel (75 mg/m²).